Swiss biotech's in­hibitor of can­cer dri­ver shows promise in rare bleed­ing dis­or­der

Vaderis Ther­a­peu­tics an­nounced Tues­day morn­ing that its lead drug can­di­date, an AKT in­hibitor, helped re­duce nose­bleeds in peo­ple with hered­i­tary he­m­or­rhag­ic telang­iec­ta­sia, a ge­net­ic dis­or­der …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER